Autologous peripheral blood stem cell transplantation for peripheral neuropathy secondary to monoclonal gammopathy of unknown significance.
A 40-year-old patient presented with rapidly progressing peripheral neuropathy secondary to monoclonal gammopathy of unknown significance (MGUS). He became severely debilitated, being wheelchair-bound, despite treatment with chemotherapy, intravenous immunoglobulin and plasma exchange. He was subsequently treated with high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (PBSCT). He has made remarkable recovery at 12 months post transplantation. We propose that high-dose chemotherapy and autologous PBSC transplantation may have a role in the treatment of severe, progressive and treatment-resistant MGUS-related peripheral neuropathy.
Lee
Y C
YC
Bone Marrow Transplantation Programme, Alfred Hospital, Melbourne, Victoria, Australia.
Came
N
N
Schwarer
A
A
Day
B
B
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000150:complications*; D009431:Neural Conduction; D010266:Paraproteins / Q000378:metabolism; D036102:Peripheral Blood Stem Cell Transplantation; D010523:Peripheral Nervous System Diseases / Q000209:etiology / Q000628:therapy*; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D016138:Walking
D010266:Paraproteins